Fierce Biotech

Innate ends work on NK cell engager in phase 1/2 trial as part of ongoing pipeline refocus

Published

2 weeks ago

on

Innate Pharma has finally called time on a NK cell engager in phase 1/2 development as part of an ongoing fine-tuning of the French biotech’s pipeline.

Related Topics:

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version